A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06561048

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:28:00.424503+00:00

Published At

2026-04-08T00:00:00+00:00

Record Updated At

2026-04-08

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Angioimmunoblastic T-cell Lymphoma", "Follicular T-Cell Lymphoma", "Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Systemic Anaplastic Large Cell Lymphoma", "Lymphoma, T-Cell, Peripheral", "Lymphoma, T-Cell"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-04-08"

protocolSection.identificationModule.nctId

"NCT06561048"

protocolSection.identificationModule.officialTitle

"A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician\u0027s Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Peripheral T-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
• Angioimmunoblastic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Follicular T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Nodal Peripheral T-Cell Lymphoma With TFH Phenotype (protocolSection.conditionsModule.conditions)
• Systemic Anaplastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Lymphoma, T-Cell, Peripheral (protocolSection.conditionsModule.conditions)
• Lymphoma, T-Cell (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.